麦澜德(688273) - 投资者关系活动记录表（2024年5月7日）

Financial Performance - In 2023, the company achieved an operating income of 340 million CNY, a decrease of 9.57% year-on-year [2] - The net profit attributable to shareholders was 89.82 million CNY, down 26.19% year-on-year [2] - R&D investment reached 58.24 million CNY, an increase of 40.89% year-on-year [2] - As of December 31, 2023, total assets amounted to 1.534 billion CNY, a year-on-year increase of 1.46% [2] - In Q1 2024, operating income was 10.4 million CNY, a decrease of 4.39% year-on-year [2] - The net profit attributable to shareholders in Q1 2024 was 36.29 million CNY, an increase of 12.04% year-on-year [2] Product Development - The company launched three new products in March 2024, including the second-generation pelvic floor biofeedback instrument [3] - The new products integrate multiple technologies for a comprehensive pelvic floor rehabilitation solution [3] - The second-generation biofeedback instrument allows for simultaneous collection of multiple physiological indicators, enhancing diagnostic accuracy [4] Market Strategy - The company aims to expand its market presence by targeting both public and private healthcare institutions [5] - It plans to enhance its product development and marketing efforts while improving operational efficiency [5] - The introduction of new products is expected to drive sales growth, supported by government initiatives promoting equipment upgrades [4] Profitability and Competition - The gross margin for pelvic floor and reproductive rehabilitation products increased by 4.54 percentage points and 1.08 percentage points, respectively, in 2023 [5] - The company has established technical barriers and diversified product strategies to enhance its competitive edge in the market [5] - Price competition exists across the industry, but the company focuses on performance and quality in its offerings [5] Future Outlook - The company anticipates continued growth in the female health and beauty sectors, with a focus on innovative technologies [6] - It plans to maintain R&D expenses at around 13%-15% over the next three years [6] - The management emphasizes a commitment to compliance and sustainable development in response to market demands [6]